Review Article

Coagulopathy of sepsis

Carl-Erik Dempfle

University Hospital of Mannheim, I. Department of Medicine, Mannheim, Germany

Summary

Disseminated intravascular coagulation (DIC) is a common phenomenon in patients with sepsis, but the clinical implications of this condition are not clear. Clinical trials with coagulation inhibitors have failed to show a significant benefit concerning survival. DIC is primarily a laboratory diagnosis, based on the combination of elevated fibrin-related markers (FRM), with decreased procoagulant factors and platelets. Non-overt DIC is observed in most patients with sepsis, whereas overt DIC is less frequent. Patients with overt DIC may display consumption coagulopathy and purpura fulminans. Consumption coagulopathy is a bleeding disorder caused by low levels of platelets and procoagulant factors associated with massive coagulation activation. Purpura fulminans is caused by widespread microvascular thrombosis, resulting in tissue necrosis. Treatment with drotrecogin alfa (activated) improves survival and other outcome parameters in severe sepsis, including a subgroup of patients fulfilling the laboratory criteria of overt DIC. No randomized trials demonstrating effective therapies in consumption coagulopathy have been published. Bleeding patients with consumption coagulopathy are most frequently treated with platelet transfusions and various plasma products including fresh frozen plasma and coagulation factor concentrates. Based on case reports, treatment with drotrecogin alfa (activated) or substitution of protein C have been recommended for adjuvant treatment of sepsis-related purpura fulminans.

Coagulation activation in sepsis

Sepsis is defined as a systemic inflammatory response syndrome occurring during infection (1). Activation of blood coagulation is a common observation in patients with sepsis (2, 3). Nearly all patients with severe sepsis according to the American College of Chest Physicians (ACCP) criteria (1) display elevated levels of activation products of blood coagulation (4). Since in most cases, no single localized clot is detected, the source of activation products is non-localized or disseminated. Coagulation activation may occur in the flowing blood, on the endothelial surface, at endothelial lesions, in the perivascular tissue, and in areas not directly linked to the vascular bed, and may or may not be associated with the formation of particulate clots.

Tissue factor production is upregulated in activated monocytes (5) and neutrophils (6) in response to endotoxin, bacterial peptidoglycans (7), or other substances (8), activating coagulation in the flowing blood (Fig. 1). Tissue factor (TF) production is regulated by nuclear factor kappa B (NFκB) (9). TF is also stored in the α-granules and the open canalicular system of resting platelets, and is exposed on the cell surface after platelet

Figure 1: Coagulation activation process in sepsis.

activation and shedding of platelet microvesicles (10). Endothelial cells may bind inflammatory cells via various adhesion molecules, again leading to activation of coagulation (11).

Apoptosis of endothelial cells (12, 13) and other cell types causes exposure of procoagulant phospholipid compounds. Released intracellular compounds such as RNA may activate coagulation via the activation of the intrinsic system (Preissner KT, personal communication) or by activation of the factor VII-activating protease (FSAP) (14, 15). Several investigators have demonstrated activation of factor XII and other components of the intrinsic system in sepsis (16, 17). Activation of the intrinsic system may also take place on the surface of bacteria (18, 19). The role of this process for the generation of thrombin remains unclear, since antibodies against factor XII were not able to prevent intravascular fibrin formation in a baboon model of *E.coli* sepsis (20). The perivascular tissue contains tissue factor-bearing cell types, alongside with other coagulation activation-promoting agents such as collagens. An increase in permeability caused by an impaired endothelial barrier leads to leakage of plasma components into the perivascular space (21, 22), bringing coagulation factors in contact with the procoagulant components of the perivascular tissue.

Although coagulation activation in sepsis is initiated by tissue factor-dependent mechanisms, the procoagulant response is dependent upon the feedback loop of coagulation activation (23, 24). Activated protein C is generated in the course of coagulation activation (25) and influences this system by inhibiting factors Va and VIIIa (26).

Coagulation activation leads to the activation of prothrombin. Thrombin cleaves fibrinopeptides A from fibrinogen. The resulting desAA-fibrin monomers rapidly polymerize with other fibrin monomers, with fibrinogen, or with proteolytic

fragments of fibrinogen and fibrin. Soluble fibrin complexes are cofactors in thrombin-induced factor XIII activation and in tPA-induced plasminogen activation. Factor XIIIa, but also non-activted 'proenzyme' factor XIII (27, 28) induce the formation of covalent bonds between fibrin monomer units within the fibrin complex. Due to a variable degree of factor XIII-induced fibrin crosslinking, and proteolytic cleavage by plasmin and other proteases such as granulocyte elastase, fibrin complexes and fibrin derivatives in patients with sepsis are heterogeneous.

Fibrin formation may occur in the flowing blood or localized at endothelial lesions or in the perivascular tissue. Assays for D-dimer antigen do not distinguish between fibrin complexes containing dimerized D-domains, and proteolytic fragments of crosslinked fibrin and do not distinguish between fibrin derivatives formed in flowing blood and fibrin derivatives released from particulate clots.

Natural anticoagulants such as antithrombin and protein C are depressed in sepsis (29). Antithrombin reacts as negative acute phase protein (30). Impaired liver function in sepsis leads to decreased protein synthesis and consequently a reduced production of hepatic coagulation factors and inhibitors. Reduced levels of antithrombin and protein C may also be caused by protein loss into the extravasal space, or coagulation activation-dependent consumption (31).

Non-overt DIC in sepsis

Non-overt DIC (32, 33) is defined as a condition of disseminated coagulation activation without clinical signs of bleeding or thrombosis. There is no conclusive evidence in humans that this 'latent coagulation' (34) in sepsis is actually part of the pathogenetic process leading to organ dysfunction or death. There is also no proof that it is an uncontrolled process or indicates decompensation of coagulation and fibrinolytic systems. The factors leading to a possible transition of non-overt DIC to overt DIC have not been identified. In general intensive care patients, the non-overt DIC score system proposed by the DIC subcommittee of the International Society for Thrombosis and Haemostasis (ISTH) (35) identified patients with increased mortality, but did not predict overt DIC (Toh CH, presentation at DIC subcommittee meeting at the ISTH congress in Birmingham, U.K., July 12th, 2003).

Alternatively, 'latent coagulation' in sepsis may be interpreted as part of the defense mechanisms of the vascular system (36). Fibrin binds active thrombin, thereby modulating *in vivo* thrombin activity (37). Fibrin is necessary for effective activation of plasminogen by tissue plasminogen activator (tPA) (38-40). In patients treated with thrombin-like snake venom enzymes such as ancrod, the presence of intravascular fibrin induces a massive profibrinolytic response, leading to intravascular fibrinogen degradation by plasmin (27, 41). In sepsis, high levels of activation products of blood coagulation and, specifi-

Table 1: Definitions of procoagulant conditions observed in sepsis.

Overt DIC	Consumption Coagulopathy	Defibrination Syndrome	Purpura fulminans
- Clinical condition which may be associated with DIC - Elevated levels of FRM - PT prolongation / Increased INR - Decreased platelet count - Decreased levels of antithrombin and protein C - (Decreased fibrinogen level)	- Laboratory criteria of overt DIC - Bleeding (wounds, puncture sites, mucous membranes, other locations)	- Presence of enzymatic activity of thrombin or thrombin-like enzymes - Elevated levels of Plasmin-antiplasmin complexes (PAP) or other indicators of plasmin generation - Elevated levels of FRM - Low fibrinogen level - Bleeding (wounds, puncture sites, mucous membranes, other locations)	- Bacterial or viral infection which may be associated with development of purpura fulminans (meningococcal or pneumococcal infections, Haemophilus, others) - Elevated levels of FRM - Low protein C levels - Microvascular thrombosis (skin, organs) - Tissue necrosis - Bleeding

cally, soluble fibrin complexes may indicate a high level of defense rather than a sign of decompensation (34).

Plasminogen activator inhibitor 1 (PAI-1) levels are often elevated in patients with sepsis (42), leading to reduced levels of tPA available for plasminogen activation despite elevated total plasma levels of tPA (43, 44). High levels of PAI-1 predict adverse outcome in severe sepsis (45). Genetic polymorphisms associated with elevated PAI-1 levels result in reduced survival in sepsis and other conditions associated with DIC (46, 47). Although most patients with sepsis, severe sepsis and septic shock display some activation of fibrinolysis (44), high plasma fibrinogen levels, despite massively elevated fibrin derivatives, indicate an imbalance between fibrin formation and fibrin degradation, potentially leading to microvascular occlusion. According to a recent study, high, rather than low plasma fibrinogen levels are associated with poor clinical outcome in DIC (48).

Sepsis-related organ dysfunction has been attributed to microvascular thrombosis (49). Animal experiments in baboons have shown fibrin deposition in the kidneys in response to infusion of high doses of live *E.coli* bacteria after priming of the immune system with an infusion of killed *E.coli*. Renal failure was prevented by infusion of active site inhibited factor VIIa (factor VIIai) before administration of the live bacteria (50). No fibrin thrombi in the microvasculature of any organ were found in animal models of hyperdynamic sepsis (51). Skjorten et al. detected microthrombi in blood vessels of various organs, including liver, lung, kidney, skin, adrenals, and heart in 100 autopsied cases of clinically suspected DIC (52). In a series of 4906 necropsies, Tanaka and Imamura found histological evidence of microvascular thrombi in 319 patients (53). Watanabe et al. detected microthrombi in two or more organs in 51/1729 patients (54). So far, no studies have systematically analyzed the relation between post-mortem evidence of microvascular thrombi and the pre-mortem diagnosis of DIC. Recent investigations based on necropsy studies in humans indicate that organ dysfunction is an effect of cell hibernation or stunning rather than thrombosis- and ischemia-induced cell necrosis (13).

Overt DIC in sepsis

Overt DIC is defined by the combination of a clinical condition, which may be associated with disseminated intravascular coagulation activation, with various laboratory criteria (Table 1). In a recent study, overt DIC, according to the laboratory criteria of the DIC subcommittee of the ISTH, was present in 22% of patients with severe sepsis (55). Although it has been shown that overt DIC has a predictive value concerning clinical outcome (56, 57), general recommendations for treatment cannot be made on the basis of this laboratory diagnosis. It must be emphasized that most authors define overt DIC on the basis of laboratory criteria (3, 35, 56, 58), in combination with underlying diseases. With this definition, overt DIC is not associated with any specific clinical symptoms. Consequently, there is no specific therapy for overt DIC.

Two diagnoses that are synonymous to overt DIC in sepsis are often used: consumption coagulopathy and purpura fulminans (Fig. 2). Consumption coagulopathy is an acquired bleeding disorder observed in patients with sepsis as well as in a variety of other diagnoses, ascribed to the consumption of procoagulant factors in the course of coagulation activation. The coagulation process may be localized such as in vascular malformations or aneurysms or non-localized as in sepsis or disseminated malignant disease. Bleeding occurs from venipuncture sites, tissue lesions, mucous membranes, or from the gastrointestinal, or genitourinary tract. In contrast to purpura fulminans, massive cutaneous bleeding is rare. A specific type of consumption coagulopathy is the defibrination syndrome (59), characterized by the combination of very low plasma fibrinogen levels, with high levels of fibrin degradation products as well as fibrinogen degradation products in plasma. Clinical and laboratory criteria for overt DIC, consumption coagulopathy, defibrination syndrome, and sepsis-associated purpura fulminans are shown in table 1.

Purpura fulminans is found in the context of meningococcal (60) pneumococcal (61), and other bacterial or viral infections (62-64). Fibrin deposits can be detected in the microvasculature

Figure 2: Clinical pathways of coagulation activation in sepsis.

of the skin and various organs (65). The descriptions of purpura fulminans by Waterhouse (66) and Friedrichsen (67) include the following characteristics: sudden onset, fever, cyanosis without dyspnea, purpuric rash, and circulatory collapse. Purpura is a condition of extravasation of cellular blood components into the skin, caused by dermal vascular thrombosis leading to hemorrhagic necrosis (68). Similar changes are observed in various organs, especially the adrenal glands and kidneys (65). Peripheral symmetrical gangrene is a subtype of purpura fulminans mainly associated with pneumococcal, streptococcal, and staphylococcal infections (69, 70). Minor forms, with necrosis of single toes or fingers are observed. Necroses occur despite normal peripheral arterial pulse. Histologic examination typically reveals the presence of thrombi in the small vessels, sparing the large vessels. Occlusion of dermal venules and capillaries by microthrombi causes hemorrhagic infarction (68). Bacteria may be present within the microthrombi, the vessel wall, and the perivascular regions. Surgical reconstructive procedures or amputation of extremities are often necessary (71, 72). Purpura fulminans resembles the experimental Shwartzman reaction induced by two injections of endotoxin given 24 hours apart (73), leading to thrombohemorrhagic skin necrosis and intravascular coagulation. Similar symptoms are found in patients with severe hereditary protein C deficiency (74-76).

Fibrinogen levels were normal in all patients reported by Cohen et al. (71), Churchwell et al. (77), and Escuriola Ettingshausen et al. (78) and in half of the cases reported by Brandzæg et al. (79).

Treatment

Treatment options for coagulation disorders related to sepsis are shown in table 2. Clinical trials aiming at an interruption of 'latent coagulation' in sepsis by administration of coagulation inhibitors such as antithrombin (80-84), heparin (85, 86), gabexate mesilate (87, 88), or tissue factor pathway inhibitor (TFPI) (89-91), have so far failed to demonstrate a statistically significant clinical benefit concerning survival (92), despite the undisputable effect on laboratory indicators of blood coagulation activation or score systems based on such parameters. An exception appears to be drotrecogin alfa (activated) (recombinant human activated protein C)(4) which caused a reduction of the relative risk of death of 19.4% in a large randomized double blind phase III study, at the cost of a slight increase in bleeding complications from 2.0% in the placebo group, to 3.5% in the patients treated with Drotrecogin alfa (activated). Other effects apart from coagulation inhibition seem to be involved in producing the clinical benefit of this treatment (93-95). Treatment with 24 µg/kg body weight per hour Drotrecogin alfa (activated) results in median plasma levels of activated protein C of 44.9ng/ml (96). Taking into consideration the normal level of activated protein C in plasma of 2 ng/ml, treatment with drotrecogin alfa (activated) produces a pharmacologic, not physiologic concentration (96). The clinical effect of Drotrecogin alfa (activated) in sepsis is most pronounced in patients with an expected high mortality such as patients with an APACHE II score of ≥25 (55, 97, 98), multiple organ dysfunction, low plate-

Table 2: Treatment options in sepsis-related coagulation disorders: Evidence from publications.

Substance	Indication	Best evidence
Drotrecogin alfa (activated)	Severe sepsis associated with high risk of death	Randomized, double-blind, placebo-controlled multicenter trial, n=1690 (4)
Drotrecogin alfa (activated)	Purpura fulminans	Case reports (150, 151)
Replacement of coagulation factors and platelets	Consumption coagulopathy	no clinical trials
Recombinant factor VIIa	Severe bleeding in consumption coagulopathy	Case reports (124, 125)
Protein C concentrate	Purpura fulminans	Case reports (78, 137, 141-145, 177-179), Phase II dose finding study (146)
Plasma exchange	Purpura fulminans	Case reports (77, 147)
r-tPA	Purpura fulminans	Case reports (153-156)

let count (55), or advanced age (99). The effect was independent of the causative microorganism (100). Treatment with drotrecogin alfa (activated) leads to more rapid dissolution of organ dysfunction in patients with severe sepsis (101). Drotrecogin alfa (activated) was effective in patients with and without the laboratory criteria of overt DIC (55). In contrast to antithrombin, heparin (102), and other anticoagulant substances (103), Drotrecogin alfa (activated) does not alter endotoxin-induced prothrombin activation and intravascular fibrin formation in the experimental setting (104). On the other hand, protein C-deficient mice develop more severe signs of intravascular coagulation, including more extensive fibrin deposition in the vasculature of various organs in response to the injection of endotoxin than mice with normal plasma protein C levels (105). Drotrecogin alfa (activated) leads to a significant decrease in plasma D-dimer antigen levels in patients with sepsis, indicating reduced intravascular fibrin formation (4). Activated protein C attenuates the inflammatory response by enzymatic action on specific protease-activated receptors (PARs), specifically PAR-1, resulting in decreased NFκB signaling (95).

One randomized prospective double blind study compared human activated protein C (not recombinant) therapy with unfractionated heparin in 104 patients with DIC (106). Death from any cause occurred in 20% of patients treated with activated protein C and 40% of patients treated with heparin (p<0.05). This may either indicate a beneficial effect of activated protein C or a hazardous effect of heparin in the patients studied. Additional data are needed to judge the role of protein C concentrates in the treatment of DIC.

The goal of antithrombin therapy performed in patients with sepsis or DIC was either reaching normal range plasma antithrombin levels or raising antithrombin levels above normal range. Cell culture experiments (107) and various animal experiments (108-110) have shown additional anti-inflammatory effects of supraphysiological concentrations of antithrombin. Blauhut et al. studied a group of 51 patients with laboratory signs of DIC of various causes, 14 of which were patients with sepsis (111). Patients received heparin, antithrombin concentrate, or a combination of both. Overall mortality was 24%, with no difference between groups. Patients with combined antithrombin and heparin therapy displayed increased bleeding. Fourrier et al. treated 35 patients with septic shock and laboratory signs of intravascular coagulation with high doses of antithrombin concentrate or placebo. Treatment with antithrombin concentrate resulted in no statistically significant benefit concerning mortality (80). Langley et al. treated 25 patients with fulminant hepatic failure with antithrombin concentrates or placebo (112) and found no difference in survival between treatment groups.

Other studies of antithrombin substitution (113), antithrombin therapy (114), or combination therapy of antithrombin with heparin (115-117) were purely observational, with no control groups or randomization.

Based on subgroup analyses of a clinical trial (83), animal, and cell culture experiments (118) it is believed that heparin competes with endothelial glucosaminoglycans for the binding of antithrombin, and therefore reduces possible local anti-inflammatory effects of antithrombin. Use of antithrombin concentrate before combined coagulation factor concentrates such as prothrombin complex concentrates (PCC) has been recommended for the prevention of coagulation activation, but no randomized trials addressing this issue have been published. Currently, there is no conclusive published evidence that antithrombin concentrates have an effect on clinical outcome in patients with sepsis, non-overt, or overt DIC.

With the use of sensitive screening techniques, a high rate of venous thromboembolism is found in intensive care patients (119-121). Antithrombin concentrates may be indicated in patients with acquired antithrombin deficiency and thromboembolism, if heparin or other antithrombin-dependent anticoagulants are used. No clinical studies on this indication have been published. Antithrombin concentrates have been used in the perioperative phase in patients with congenital antithrombin deficiency, but no reports have been published on the use of antithrombin concentrate in patients with congenital antithrombin deficiency and sepsis.

Replacement of coagulation factors and platelets represents the most convincing approach for the treatment of a bleeding disorder associated with a deficiency in these compounds, as present in consumption coagulopathy. No systematic studies on the use of fresh frozen plasma, cryoprecipitate, coagulation factor concentrates, fibrinogen concentrate, or platelet transfusions in patients with sepsis-associated consumption coagulopathy have been published. Recommendations are generally based on theoretical assumptions and analogy with inherited or other acquired bleeding disorders. Similarly, the use of antifibrinolytic drugs in consumption coagulopathy is anecdotal (122). There is no evidence from published clinical studies that platelet transfusions and treatment with coagulation factor preparations 'fuels the fire' of intravascular coagulation activation.

Low factor VIIa plasma levels were measured in neutropenic patients with severe sepsis (123). Recombinant factor VIIa has been used for treatment of a variety of severe bleeding disorders and case reports have been published on the use of this drug in patients with consumption coagulopathy (124, 125). Many clinicians will be hesitant to use a massively procoagulant drug in patients with preexisting systemic coagulation activation. Further investigations are needed to clarify if consumption coagulopathy is an indication for the treatment with recombinant factor VIIa.

Bleeding in defibrination syndrome may be due to the absence of adequate amounts of fibrinogen, especially in patients with trauma. Alternatively, it may be the result of fibrinolytic activation, leading to rapid degradation of fibrin clots at vascular lesions. Substitution of fibrinogen by use of fibrinogen concentrates or plasma protein preparations with high concentrations of fibrinogen such as cryoprecipitate (126, 127), may be helpful in bleeding patients with defibrination syndromes. According to the results of Hesselvik et al., treatment with cryoprecipitate does not seem to aggravate coagulation activation in patients with DIC (126). Patients with hyperfibrinolysis may profit from treatment with antifibrinolytic drugs such as tranexamic acid (122, 128). There are no standardized laboratory criteria for the diagnosis of hyperfibrinolysis, making the decision for treatment with antifibrinolytic drugs rather difficult. Additional substitution of factor XIII may be advantageous in patients with deficient wound healing (129), although depletion of factor XIII has been shown to prevent organ damage in an animal model of LPS-induced Shwartzman reaction (130). No randomized trials of fibrinogen- or factor XIII substitution in sepsis, consumption coagulopathy, or defibrination syndrome have been published.

Since microvascular thrombosis is regarded as the predominant pathophysiological feature of purpura fulminans, the majority of therapeutic approaches are aimed at a reduction of coagulation activation and improvement of fibrinolysis. Heparin has been suggested (131-133), but no randomized trials have been published. Antithrombin concentrates have been used

in patients with purpura fulminans (134-136), but again no randomized trials are available.

Patients with purpura fulminans and multiorgan failure in meningococcal infection have significantly higher plasma PAI-1 levels as well as lower protein C and antithrombin levels than patients with meningococcal infection, but without purpura or organ failure (137, 138). In view of the low protein C levels in purpura fulminans (139), numerous case reports of protein C replacement as well as open label studies have been published (78, 137, 140-146). Only a dose of 150 IU/kg body weight or more given every 6 hours resulted in significantly increased levels of activated protein C in patients with purpura fulminans, whereas lower doses failed to cause an increase in activated protein C levels (146). A dose of 600 IU/kg body weight per day increased plasma protein C levels to 2-3 IU/ml and activated protein C levels to three- to fourfold of baseline (146). No effect of protein C concentrate infusion on mortality was found in the phase II dose finding study (146). In the case series published by Escuriola Ettingshausen et al. (78), protein C substitution lead to a rapid decrease in plasma PAI-1 levels. Plasma exchange may be an alternative source of protein C and other plasma components deficient in purpura fulminans (77, 79, 147).

Due to the impaired activation of protein C in severe sepsis (148, 149) it seems logical to use activated protein C in patients with sepsis-induced purpura fulminans. Case reports have been published on the use of drotrecogin alfa (activated) in meningococcal sepsis (150, 151). Activated protein C forms an inactive complex with PAI-1, reducing the functional plasma levels of PAI-1 (152).

An alternative to the inhibition of PAI-1 by activated protein C in purpura fulminans might be treatment with profibrinolytic agents such as tPA (153-156). Only case reports are available and no randomized trials have been performed. A significant proportion of patients treated with tPA suffer from intracerebral hemorrhage, a complication not reported to date for treatment of purpura fulminans with protein C concentrates. Due to these reported cases of intracerebral hemorrhage, it is unlikely that a randomized trial on the use of tPA in purpura fulminans will be performed.

Treatment options: expert suggestions

Heparin / low molecular weight heparin

It has been suggested that treatment with heparin may reduce the anti-inflammatory effect of antithrombin, but no randomized trials comparing patients with sepsis with or without heparin therapy have been published. Due to the high rate of venous thrombosis and pulmonary embolism in ICU patients (157-159), low dose heparin therapy is also standard care in patients with

sepsis. Venous access devices often induce the formation of intravascular clots (160), which may promote bacteraemia (161). Since the bioavailability of unfractionated heparin is reduced in the presence of high levels of acute phase proteins (162-164), low molecular weight heparin is preferred. Bioavailability of unfractionated and low molecular weight heparin given subcutaneously is lower in patients treated with catecholamines due to vasoconstriction (165, 166). A dose of 40mg of enoxaparin (159) or 3800 aXa-units of nadroparin (167) or 5000 aXa units of dalteparin per day are recommended. Unfractionated heparin or low molecular weight heparin for thrombosis prophylaxis may be unnecessary in patients treated with drotrecogin alfa (activated) due to the antithrombotic properties of this drug.

In patients treated with continuous hemofiltration unfractionated heparin, low molecular weight heparin (168) or heparinoids are used. Patients treated with unfractionated heparin receive an initial bolus of 2000-5000 IU of heparin, followed by an infusion of 10IU/kg per hour. Doses are adjusted to maintain an aPTT in the range of 70-80 seconds. When using unfractionated heparin in sepsis patients it should be kept in mind that the activated clotting time (ACT) shows little correlation with the actual level of unfractionated heparin in critically ill patients, and therefore should not be used for treatment monitoring (169). On the other hand the aPTT in patients with sepsis is often prolonged due to low factor XII levels (29). If aPTT prolongation is caused by factor XII deficiency, thrombin time is within normal range. Therefore parallel measurement of aPTT and thrombin time is recommended in sepsis patients treated with therapeutic doses of unfractionated heparin.

For continuous hemofiltration, dalteparin is given as initial bolus of 5-20aXa-units/kg body weight, followed by 5-10aXa-units/kg per hour (168, 170). Similar doses of nadroparin may be used (170). In patients treated with drotrecogin alfa (activated), additional heparin may be unnecessary during continuous hemofiltration (171).

Antithrombin
Antithrombin replacement is indicated in patients with continuous hemofiltration or other extracorporal circulation procedures and low plasma antithrombin levels, if unfractionated heparin or low molecular weight heparin is used for anticoagulation. Target is a normal range antithrombin level. Suggestions for dosages stem from studies on patients with heparin resistance undergoing cardiac surgery (172, 173). Antithrombin levels should be measured daily during continuous hemofiltration or similar procedures. Patients with sepsis and venous thrombosis or pulmonary embolism treated with unfractionated heparin or low molecular weight heparin, as well as patients with hereditary antithrombin deficiency should also receive antithrombin concentrates if the plasma antithrombin level is below 60% of normal. Patients treated with prothrombin complex concentrate (PCC) should receive antithrombin concentrates if the plasma antithrombin level is below 40% of normal.

Drotrecogin alfa (activated)
The approved indication for treatment with drotrecogin alfa (activated) is severe sepsis associated with organ dysfunction, independent of the presence of disseminated intravascular coagulation. Treatment guidelines are therefore focused on the presence of infection, systemic inflammatory response syndrome (SIRS), and organ dysfunction. Clinical score systems, such as the APACHE II score may aid in the selection of patients. A reduced platelet count is regarded as an indicator for the dysfunction of the hemostatic system. Coagulation activation parameters are not taken into consideration. Patients with sepsis-related purpura fulminans or consumption coagulopathy generally fulfill the criteria for adjuvant therapy with drotrecogin alfa (activated), therefore no additional guidelines are needed. Patients are treated with 24 µg/kg body weight per hour for 96 hours.

Protein C concentrate
Beneficial effects of plasma-derived protein C concentrate have been reported in sepsis-induced purpura fulminans. The recommended dosage is 100-600 IU/kg body weight every 6 hours.

Platelets
A reduced platelet count in patients with sepsis may be due to reduced platelet synthesis, blood loss, platelet consumption by coagulation activation, and by hemophagocytosis (174, 175). In the absence of bleeding or other irregularities of coagulation, platelet counts of 5000/µl may be tolerated. In patients with sepsis, the trigger for platelet transfusion should be a platelet count of 20000/µl in the absence of bleeding, and 50000/µl in the presence of bleeding or before invasive procedures or surgery. In patients with severely impaired platelet function, higher levels may be needed. In severely bleeding patients treated with recombinant factor VIIa, the platelet count should be kept above 20000/µl. An optimal dose of platelets has not been established, but typically doses equivalent to five to six random donor platelet concentrates are given initially. Further dosing depends upon the individual response to treatment.

Cryoprecipitate

Cryoprecipitate is a plasma-derived product that contains fibrinogen, factor VIII, von Willebrand factor, and factor XIII. It may, therefore, serve as source for these proteins if purified factor concentrates are not available. One unit of cryoprecipitate per 10kg body weight increases the plasma fibrinogen concentration by 0.4-0.5 g/l.

Fibrinogen concentrate

The threshold for fibrinogen substitution in patients with sepsis-induced coagulation disorders has not been established. Based on personal experiences, fibrinogen substitution may be helpful in patients with active bleeding and plasma fibrinogen levels below 1g/l.

Factor XIII concentrate

Although very low levels of factor XIII are sufficient to induce gamma-chain crosslinking in fibrin, effective wound healing requires higher levels of factor XIII. In patients with trauma or major surgery and inefficient wound healing, factor XIII levels above 50% should be maintained. A single dose of 25-50 IU/kg body weight of factor XIII concentrate is usually sufficient. Higher or repetitive doses may be needed in patients with burn injury or intestinal bleeding.

Fresh frozen plasma (FFP)

In patients with sepsis, prolonged PT and aPTT, and active bleeding or invasive procedures, FFP may be used at a dose of 10-15 ml/kg body weight. Additional doses are given based on clinical and laboratory evaluation. Physiologically tolerable quantities of FFP result only in a 20%-30% increase in the levels of coagulation factors. Due to different plasma half life of coagulation factors, repeated FFP administration may result in an imbalance between coagulation factors with long and short half life. Treatment with FFP may not be sufficient to normalize plasma factor VII levels in patients with sepsis. Plasma exchange has been used in patients with sepsis-induced purpura fulminans (77).

Prothrombin complex concentrate (PCC)

Prothrombin complex concentrates are helpful in bleeding patients with sepsis and vitamin K-deficiency, or as part of a combined strategy involving PCC and fresh frozen plasma. PCC contains coagulation factors II, VII, IX, and X, as well as protein C and protein S. In patients with impaired liver function, PCC may fail to correct an abnormal PT since it does not contain factor V. FFP may serve as source of factor V and other coagulation factors no present in PCC. Doses of 20-30 units/kg body weight of PCC are recommended.

Recombinant factor VIIa

Recombinant factor VIIa may be used in patients with severe bleeding not responsive to other treatment options. Bolus doses of 60-120 µg/kg body weight are given. The bolus may be repeated after 2-6 hours if necessary. If the platelet count is below 20000/µl patients should receive platelet transfusions in parallel since the effect of recombinant factor VIIa is dependent upon an intact platelet surface (176). Patients with head trauma, thromboembolic conditions, stroke or coronary heart disease should not be treated with recombinant factor VIIa.

Desmopressin

Desmopressin (DDAVP or 1-deamino,8-D-arginine vasopressin) stimulates the release of von Willebrand factor, factor VIII, and tPA from endothelial cells, and is used in patients with mild hemophilia A or von Willebrand disease. Desmopressin may cause inappropriate water retention and subsequent hyponatremia. Since plasma levels of von Willebrand factor and factor VIII are typically elevated in patients with sepsis, desmopressin has little effect on bleeding in these patients. Currently, desmopressin cannot be recommended in bleeding patients with sepsis-induced coagulation disorders.

References

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101(6): 1644-55.
2. Mavrommatis AC, Theodoridis T, Orfanidou A, et al. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 200; 28(2): 451-7.
3. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost 1980; 43(1): 28-33.
4. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10): 699-709.
5. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S9-14.
6. Todoroki H, Nakamura S, Higure A, et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127(2): 209-16.
7. Mattsson E, Herwald H, Bjorck L, et al. Peptidoglycan from Staphylococcus aureus induces tissue factor expression and procoagulant activity in human monocytes. Infect Immun 2002; 70(6): 3033-9.
8. Mirlashari MR, Hoiby EA, Holst J, et al. Outer membrane vesicles from Neisseria meningitidis: effects on tissue factor and plasminogen activator inhibitor-2 production in human monocytes. Thromb Res2001; 102(4): 375-80.
9. Bohrer H, Qiu F, Zimmermann T, et al. Role of NFkappaB in the mortality of sepsis. J Clin Invest 1997; 100(5): 972-85.
10. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. Faseb J 2003; 17(3): 476-8.
11. Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002; 30 (5 Suppl): S220-4.
12. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Endothelial cell apoptosis in sepsis. Crit Care Med 2002; 30(5 Suppl): S225-8.
13. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27(7):1230-51.

14. Kannemeier C, Feussner A, Stohr HA, et al. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem 2001; 268(13): 3789-96.

15. Romisch J. Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 2002; 383(7-8): 1119-24.

16. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988; 72(6): 1841-8.

17. Wuillemin WA, Fijnvandraat K, Derkx BH, et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995; 74(6): 1436-41.

18. Herwald H, Morgelin M, Olsen A, et al. Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases. Nat Med 1998; 4(3): 298-302.

19. Persson K, Russell W, Morgelin M, et al. The conversion of fibrinogen to fibrin at the surface of curliated E. coli bacteria leads to the generation of proinflammatory fibrinopeptides. J Biol Chem 2003; 278: 31884-90.

20. Pixley RA, De La Cadena R, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91(1): 61-8.

21. Dormehl IC, Hugo N, Knoessen O. In vivo assessment of regional microvascular albumin leakage during E. coli septic shock in the baboon model. Am J Physiol Imaging 1991; 6(2): 81-4.

22. Lush CW, Kvietys PR. Microvascular dysfunction in sepsis. Microcirculation 2000; 7(2): 83-101.

23. Gailani D, Broze, GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253(5022): 909-12.

24. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med 2001; 29(7 Suppl): S28-34; discussion S34-5.

25. Alcaraz A, Espana F, Sanchez-Cuenca J, et al. Activation of the protein C pathway in acute sepsis. Thromb Res 1995; 79(1): 83-93.

26. Giles AR, Nesheim ME, Mann KG. Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest 1984 74(6): 2219-25.

27. Dempfle CE, Argiriou S, Kucher K, et al. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod. Blood 2000; 96(8): 2793-802.

28. Siebenlist KR, Meh DA, Mosesson MW. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 2001; 86(5): 1221-8.

29. Hesselvik JF, Blomback M, Brodin B, et al. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17(8): 724-33.

30. Niessen RW, Lamping RJ, Jansen PM, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78(3): 1088-92.

31. Boldt J, Papsdorf M, Rothe A, et al. Changes of the hemostatic network in critically ill patients – is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med 2000; 28(2): 445-50.

32. Taylor FB, Jr., Wada H, Kinasewitz G. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: toward a better definition of DIC. Crit Care Med 2000; 28(9 Suppl):S12-9.

33. Wada H, Wakita Y, Nakase T, et al. Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group. Pol J Pharmacol 1996; 48(2): 225-8.

34. Lasch HG. [Clinical aspects and therapy of disseminated intravascular coagulation]. Hamatol Bluttransfus1970; 9:121-31.

35. Taylor FB, Jr., Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86(5): 1327-30.

36. Sjobring U, Ringdahl U, Ruggeri ZM. Induction of platelet thrombi by bacteria and antibodies. Blood 2002; 100(13): 4470-7.

37. Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89(1):9-12.

38. Lijnen HR, Soria J, Soria C, et al. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984; 51(1): 108-9.

39. Mosesson MW, Siebenlist KR, Voskuilen M, et al. Evaluation of the factors contributing to fibrin-dependent plasminogen activation. Thromb Haemost 1998; 79(4): 796-801.

40. Yakovlev S, Makogonenko E, Kurochkina N, et al. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 2000; 39(51): 15730-41.

41. Dempfle CE, Argiriou S, Alesci S, etal. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity. Ann N Y Acad Sci 2001; 936: 210-4.

42. Watanabe R, Wada H, Miura Y, et al. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 2001; 7(3): 229-33.

43. Francis RB, Jr., Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations. J Lab Clin Med 1987; 110(5): 541-7.

44. Mavrommatis AC, Theodoridis T, Economou M, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 2001; 27(12): 1853-9.

45. Mesters RM, Florke N, Ostermann H, et al. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75(6): 902-7.

46. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354(9178): 556-60.

47. Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357(9262): 1096-7.

48. Wada H, Mori Y, Okabayashi K, et al. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol 2003; 72(1):1-7.

49. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999, 341(8): 586-92.

50. Welty-Wolf KE, Carraway MS, Miller DL, et al: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164(10 Pt 1): 1988-96.

51. Hersch M, Gnidec A, Bersten AD, et al. Histologic and ultrastructural changes in non-pulmonary organs during early hyperdynamic sepsis. Surgery1990; 107(4): 397-410.

52. Skjorten F. Hyaline microthrombi in an autopsy material. A quantitative study with discussion of the relationship to small vessel thrombosis. Acta Pathol Microbiol Scand 1969; 76(3): 361-75.

53. Tanaka K, Imamura T. Incidence and clinico-pathological significance of DIC in autopsy cases. Bibl Haematol 1983; (49): 79-93.

54. Watanabe T, Imamura T, Nakagaki K, et al. Disseminated intravascular coagulation in autopsy cases. Its incidence and clinicopathologic significance. Pathol Res Pract 1979; 165(3): 311-22.

55. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31(1): 12-9.

56. Wada H, Wakita Y, Nakase T, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 1995; 74(3): 848-52.

57. Gando S, Nanzaki S, Kemmotsu O. Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. Ann Surg 1999; 229(1): 121-7.

58. Bredbacka S, Blomback M, Wiman B, et al. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesthesiol Scand 1993; 37(2): 125-30.

59. Regan DH, Lackner H. Defibrination syndrome: changing concepts and recognition of the low grade form. Am J Med Sci 1973; 266(2): 84-91.

60. Haslund R. Waterhouse Friderichsen syndrome. Endotoxin shock treated with massive doses of cortisol. J Oslo City Hosp 1973; 23(3): 49-64.

61. Auburtin M, Porcher R, Bruneel F, et al. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases. Am J Respir Crit Care Med 2002; 165(5): 713-7.

62. Lineaweaver W, Branzini D, Dragonetti D, et al. Hemophilus influenzae meningitis and Waterhouse-Friderichsen syndrome in an adult. South Med J 1986; 79(8): 1034-6.

63. Canpolat C, Bakir M. A case of purpura fulminans secondary to transient protein C deficiency as a complication of chickenpox infection. Turk J Pediatr 2002; 44(2): 148-51.

64. Karakousis PC, Page KR, Varello MA, et al. Waterhouse-Friderichsen syndrome after infection with group A streptococcus. Mayo Clin Proc 2001; 76(11): 1167-70.

65. Fox B. Disseminated intravascular coagulation and the Waterhouse-Friderichsen syndrome. Arch Dis Child 1971; 46(249): 680-5.

66. Waterhouse R. A case of suprarenal apoplexy. Lancet 1911; 1: 577-8.

67. Friedrichsen C. Waterhouse-Friedrichsen's syndrome. Acta Endocrin 1955; 18: 482-92.

68. Adcock DM, Hicks MJ. Dermatopathology of skin necrosis associated with purpura fulminans. Semin Thromb Hemost 1990; 16(4): 283-92.

69. Johansen K, Hansen, ST Jr. Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis. Am J Surg 1993; 165(5): 642-5.

70. Parmar MS. Symmetrical peripheral gangrene: a rare but dreadful complication of sepsis. Cmaj 2002; 167(9): 1037-8.

71. Cohen JR, Lackner R, Keller, A, et al. The surgical implications of purpura fulminans. Ann Vasc Surg 1990; 4(3): 276-9.

72. Silbart S, Oppenheim W. Purpura fulminans. Medical, surgical, and rehabilitative considerations. Clin Orthop 1985; (193): 206-13.

73. Brozna JP. Shwartzman reaction. Semin Thromb Hemost 1990; 16(4): 326-32.

74. Muller FM, Ehrenthal W, Hafner G, et al. Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr 1996; 155(1): 20-5.

75. Nakayama T, Matsushita T, Fidano H, et al. A case of purpura fulminans is caused by homozygous delta8857 mutation (protein C-nagoya) and successfully treated with activated protein C concentrate. Br J Haematol 2000; 110(3):727-30.

76. Soria JM, Morell M, Jimenez-Astorga C, et al. Severe type I protein C deficiency in a compound heterozygote for Y124C and Q132X mutations in exon 6 of the PROC gene. Thromb Haemost 1995; 74(5): 1215-20.

77. Churchwell KB, McManus ML, Kent P, et al. Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia. J Clin Apheresis 1995; 10(4):171-7.

78. Ettingshausen CE, Veldmann A, Beeg T, et al. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 1999; 25(6): 537-41.

79. Brandtzaeg P, Sirnes K, Folsland B, et al. Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis. Preliminary data on eight patients. Scand J Clin Lab Invest Suppl 1985; 178: 53-5.

80. Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104(3): 882-8.

81. Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24(4):336-42.

82. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24(7): 663-72.

83. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama 2001; 286(15): 1869-78.

84. Inthorn D, Hoffmann JN, Hartl WH, et al. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock 1997; 8(5): 328-34.

85. Lasch HG, Heene DH. Heparin therapy of diffuse intravascular coagulation (DIC). Thromb Diath Haemorrh 1975; 33(1): 105-6.

86. Corrigan JJ, Jr., Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med 1970; 283(15): 778-82.

87. Nishiyama T, Matsukawa T, Hanaoka K. Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation? Crit Care Med 2000; 28(5): 1419-22.

88. Taenaka N, Shimada Y, Hirata T, et al. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 1983; 11(9): 735-8.

89. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95(4): 1124-9.

90. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29(11): 2081-9.

91. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Jama 2003; 290(2): 238-47.

92. Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 2003; 20(1): 5-9.

93. Vincent JL. Drotrecogin alfa: a new approach in the treatment of severe sepsis. Expert Opin Biol Ther 2002; 2(6): 659-64.

94. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296(5574): 1880-2.

95. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 2002; 30(5 Suppl): S288-93.

96. Macias WL, Dhainaut JF, Yan SC, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72(4): 391-402.

97. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347(13): 993-1000.

98. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31(1): 1-11.

99. Ely EW, Angus DC, Williams MD, et al. Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003; 37(2): 187-95.

100. Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37(1): 50-8.

101. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31(3): 834-40.

102. Pernerstorfer T, Hollenstein U, Hansen J, et al. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999; 100(25): 2485-90.

103. Pernerstorfer T, Hollenstein U, Hansen JB, et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000; 95(5): 1729-34.

104. Derhaschnig U, Reiter R, Knobl P, et al. Recombinant human activated protein C (rhAPC, drotrecogin alfa activated) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-8.

105. Levi M, Dorffler-Melly J, Reitsma P, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 2003; 101(12): 4823-7.

106. Aoki N, Matsuda T, Saito H, et al. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 2002; 75(5): 540-7.

107. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99(11): 4015-20.

108. Kessler CM, Tang Z, Jacobs HM, et al. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997; 89(12): 4393-401.

109. Hoffmann JN, Vollmar B, Inthorn D, et al. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 2000; 279(1): C98-C107.

110. Hoffmann JN, Vollmar B, Romisch J, et al. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30(1): 218-25.

111. Blauhut B, Kramar H, Vinazzer H, et al. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985; 39(1): 81-9.

112. Langley PG, Hughes RD, Forbes A, et al. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 1993; 17(3): 326-31.

113. Schipper HG, Jenkins CS, Kahle LH, et al. Antithrombin-III transfusion in disseminated intravascular coagulation. Lancet 1978; 1(8069): 854-6.

114. Fuse S, Tomita H, Yoshida M, et al. High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children. Am J Hematol 1996; 53(1): 18-21.

115. Blauhut B, Necek S, Vinazzer H, et al. Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 1982; 27(3): 271-8.

116. Hellgren M, Javelin L, Hagnevik K, et al. Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients. Thromb Res 1984; 35(4): 459-66.

117. Kreuz WD, Schneider W, Nowak-Gottl U. Treatment of consumption coagulopathy with antithrombin concentrate in children with acquired antithrombin deficiency – a feasibility pilot study. Eur J Pediatr 1999; 158(Suppl 3): S187-91.

118. Hoffmann JN, Vollmar B, Laschke MW, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88(2): 242-52.

119. Marik, P. E., L. Andrews, and B. Maini. 1997. The incidence of deep venous thrombosis in ICU patients. Chest 111(3):661-4.

120. Anderson DR, Wells PS, Stiell L, et al. Thrombosis in the emergency department: use of a clinical diagnosis model to safely avoid the need for urgent radiological investigation. Arch Intern Med 1999; 159(5): 477-82.

121. Attia J, Ray JG, Cook DJ, et al. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001; 161(10): 1268-79.

122. Takada A, Takada Y, Mori T, et al. Prevention of severe bleeding by tranexamic acid in a patient with disseminated intravascular coagulation. Thromb Res 1990; 58(2):101-8.

123. Mesters RM, Mannucci PM, Coppola R, et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88(3): 881-6.

124. Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 114(1): 174-6.

125. Chuansumrit A, Chantarojanasiri T, Isarangkura P, et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S101-5.

126. Hesselvik F, Brodin B, Blomback M, et al. Fibronectin and other DIC-related variables in septic ICU patients receiving cryoprecipitate. Scand J Clin Lab Invest Suppl 1985; 178: 67-74.

127. Brodin B, Hesselvik F, Blomback M, et al. Fibronectin and other DIC-related variables in patients with moderately severe infections receiving cryoprecipitate. Scand J Clin Lab Invest Suppl 1985; 178: 57-65.

128. Sugawara T, Okuda M, Yamaguchi Y, et al. Successful treatment with tranexamic acid for severe bleeding in acute promyelocytic leukemia. Acta Haematol 1992; 87(1-2): 109.

129. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12(2):101-8.

130. Lee SY, Chang SK, Lee IH, et al. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. Thromb Haemost 2001; 85(3): 464-9.

131. Hunter J. Heparin therapy in meningococcal septicaemia. Arch Dis Child 1973; 48(3): 233-5.

132. Chu DZ, Blaisdell FW. Purpura fulminans. Am J Surg 1982; 143(3): 356-62.

133. Wilson FE, Morse SR. Therapy of acute meningococcal infections: early volume expansion and prophylactic low dose heparin. Am J Med Sci 1972; 264(6): 445-55.

134. Fourrier F, Lestavel P, Chopin C, et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16(2): 121-4.

135. Cobcroft R, Henderson A, Solano C, et al. Meningococcal purpura fulminans treated with antithrombin III concentrate: what is the optimal replacement therapy? Aust N Z J Med 1994; 24(5):575-6.

136. Mertens R, Peschgens T, Granzen B. Diagnosis and stage-related treatment of disseminated intravascular coagulation in meningococcal infections. Klin Padiatr 1999; 211(2): 65-9.

137. White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96(12): 3719-24.

138. Brandtzaeg P, Joo GB, Brusletto B, et al. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57(2): 271-8.

139. Madden RM, Gill JC, Marlar RA. Protein C and protein S levels in two patients with acquired purpura fulminans. Br J Haematol 1990; 75(1): 112-7.

140. Dreyfus M, Masterson M, David M, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995; 21(4): 371-81.

141. Rivard GE, David M, Farrell C, et al. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995; 126(4): 646-52.

142. Kreuz W, Veldman A, Escuriola-Ettingshausen C, et al. Protein-C concentrate for meningococcal purpura fulminans. Lancet 1998; 351(9107): 986-7; discussion 988.

143. Rintala E, Seppala O, Kotilainen P, et al. Protein C in the treatment of coagulopathy in meningococcal disease. Lancet 1996; 347 (9017): 1767.

144. Rintala E, Seppiala OP, Kotilainen P, et al. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 1998; 26(5): 965-8.

145. Rintala E, Kauppila M, Seppiala OP, et al. Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 2000; 28(7): 2373-8.

146. de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans:

a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31(6): 1839-47.

147. Hodgson A, Ryan T, Moriarty J, et al. Plasma exchange as a source of protein C for acute onset protein C pathway failure. Br J Haematol 2002; 116(4): 905-8.

148. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29(7 Suppl): S69-74.

149. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345(6): 408-16.

150. Weisel G, Joyce D, Gudmundsdottir A, et al. Human recombinant activated protein C in meningococcal sepsis. Chest 2002; 121(1): 292-5.

151. Bachli EB, Vavricka SR, Walter RB, et al Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med 2003; 29(2): 337.

152. Aoki Y, Ota M, Katsuura Y, et al. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneimittelforschung 2000; 50(9): 809-15.

153. Zenz W, Muntean W, Zobel G, et al. Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator. Thromb Haemost 1995; 74(2): 802-3.

154. Zenz W, Muntean W, Gallistl S, et al. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 1995; 96(1 Pt 1): 44-8.

155. Zenz W, Bodo Z, Zobel G, et al. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 1998; 26(5): 969-71; discussion 972-3.

156. Aiuto LT, Barone SR, Cohen PS, et al. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 1997; 25(6): 1079-82.

157. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. Jama 1995; 274(4): 335-7.

158. Moser KM, LeMoine JR, Nachtwey FJ, et al. Deep venous thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit. Jama 1981; 246(13): 1422-4.

159. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341(11): 793-800.

160. Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. Jama 2001; 286(6): 700-7.

161. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. Chest 1998; 114(1): 207-13.

162. Young E, Podor TJ, Venner T, et al. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997; 17(8): 1568-74.

163. Cosmi B, Fredenburgh JC, Rischke J, et al. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 1997; 95(1): 118-24.

164. Manson L, Weitz JI, Podor TJ, et al. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med 1997; 130(6): 649-55.

165. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003; 31(5):1405-9.

166. Dorffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359(9309): 849-50.

167. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000; 161(4 Pt 1): 1109-14.

168. Reeves JH, Cumming AR, Gallagher L, et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999; 27(10): 2224-8.

169. De Waele JJ, Van Cauwenberghe S, Hoste E, et al. The use of the activated clotting time for monitoring heparin therapy in critically ill patients. Intensive Care Med 2003; 29(2): 325-8.

170. de Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, et al. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Crit Care Med 2000; 28(2): 421-5.

171. De Pont AC, Bouman CS, De Jonge E, et al. Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis. Intensive Care Med 2003; 29(7): 1205.

172. Lemmer JH, Jr., Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123(2): 213-7.

173. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70(3): 873-7.

174. Francois B, Trimoreau F, Vignon P, et al. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997; 103(2): 114-20.

175. Trimoreau F, Francois B, Desachy A, et al. Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome. Mediators Inflamm 2000; 9(3-4): 197-200.

176. Hoffman M, Monroe DM, 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 Suppl 1: S61-5.

177. Alberio L, Lammle B, Esmon CT. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 2001; 32(9): 1338-46.

178. Betrosian AP, Balla M, Kofinas G, et al. Protein C in the treatment of coagulopathy in meningococcal sepsis. Crit Care Med 1999; 27(12): 2849-50.

179. Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350(9091): 1590-3.